{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0098","upperLimit":"0.2603","value":"0.0800"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0.1482","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0.1951","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"Confirmed response is defined to be a partial response, nodular partial response, clinical complete response, confirmed response with incomplete blood count recovery or confirmed response (Arm A and B), or complete metabolic response, partial metabolic response, partial response, or confirmed response (Arm C). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial confidence intervals for the true success proportion will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG000","title":"Arm A (CLL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG001","title":"Arm B (NHL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG002","title":"Arm C (CLL With Richters)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Proportion of Patients Who Achieve a Confirmed Response","type":"PRIMARY","unitOfMeasure":"proportion of responders"}